Arena (ARNA) Looks to Break Losing Streak Following Qsymia Approval (VVUS) (OREX)
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals (Nasdaq: ARNA) shares are skipping over broader market moves Monday, as well as outpacing its peers, on some positive sentiment.
Volatility on Arena is down 3 percent to 5.2 percent and at 55 percent of its annual average.
Shares are up about 7.5 percent on the session, breaking a five-session losing streak.
Despite the recent move lower, Arena is still trading up about 450 percent in 2012, bolstered by a positive FDA panel vote for Belviq on May 10th and subsequent approval on June 27th. Peer VIVUS (Nasdaq: VVUS) recently received FDA approval for its own weight-management pill, Qsymia, while Orexigen (Nasdaq: OREX) is still conducting trials on its Contrave to evaluate its effects on the heart.
Volatility on Arena is down 3 percent to 5.2 percent and at 55 percent of its annual average.
Shares are up about 7.5 percent on the session, breaking a five-session losing streak.
Despite the recent move lower, Arena is still trading up about 450 percent in 2012, bolstered by a positive FDA panel vote for Belviq on May 10th and subsequent approval on June 27th. Peer VIVUS (Nasdaq: VVUS) recently received FDA approval for its own weight-management pill, Qsymia, while Orexigen (Nasdaq: OREX) is still conducting trials on its Contrave to evaluate its effects on the heart.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Musalem: strong growth and investment influencing bond market - CNBC
- Anthropic to update data retention policy for enterprise customers - Bloomberg
- Nvidia plans China chip shipments with export-compliant AI processor - The Information
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
